CC

Chetna Chouhan

Active Director Director DIN 06442572
DIN 06442572 First appointment Mar 2013 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2013
Shareholding value •••• Premium profile

About Chetna Chouhan

Data last updated:

Chetna Chouhan is a Director at Anglo-Indian Pharmaceuticals Private Limited (since 2013). The company operates in Pharma. Anglo-Indian Pharmaceuticals Private Limited reported revenue of ₹1.12 Cr (FY 2025).

DIN 06442572
Primary Designation Director
Industry Pharma
First Appointment 14 Mar 2013
Oldest Company Age 13 yrs
Largest company Anglo-Indian Pharmaceuticals Private Limited · ₹1.12 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director14 Mar 20132013₹1.12 Cr (FY 2025)Active

Board colleagues of Chetna Chouhan

Directorship timeline

Open interactive timeline →
Anglo-Indian Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Chetna Chouhan

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Chetna Chouhan

Chetna Chouhan currently holds 1 directorship: Anglo-Indian Pharmaceuticals Private Limited (Director, since 14 Mar 2013, revenue ₹1.12 Cr (FY 2025)).

Chetna Chouhan was first appointed on 14 Mar 2013 as Director at Anglo-Indian Pharmaceuticals Private Limited.

The current boards of Chetna Chouhan's companies include Dharmendra Singh Chouhan (Anglo-Indian Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available